REGN

Regeneron Pharmaceuticals (REGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Sanofi Pays Regeneron $1.0 Billion Upfront For Four Antibodies, With Up To $7.0 Billion More In Milestones

SEC Filings

Sanofi Pays Regeneron $1.0 Billion Upfront For Four Antibodies, With Up To $7.0 Billion More In Milestones

An 8-K shows the partners settled Regeneron's Dupixent information lawsuit and will split global profits equally on four new antibodies.

Regeneron Locks Co-Founders Into A Decade Of Performance Targets — No New Equity Until 2036

SEC Filings

Regeneron Locks Co-Founders Into A Decade Of Performance Targets — No New Equity Until 2036

A one-time grant of up to 5.6 million performance share units ties CEO Leonard Schleifer and CSO George Yancopoulos to a $30 billion revenue target.